— Know what they know.
Not Investment Advice

LQDA NASDAQ

Liquidia Corporation
1W: +9.5% 1M: +9.8% 3M: +126.3% YTD: +168.8% 1Y: +349.8% 3Y: +948.7% 5Y: +3317.8%
$86.82
+2.40 (+2.84%)
 
Weekly Expected Move ±9.9%
$69 $78 $86 $95 $103
NASDAQ · Healthcare · Medical - Pharmaceuticals · Alpha Radar Buy · Power 68 · $7.7B mcap · 62M float · 3.15% daily turnover · Short 71% of daily vol
Smart Money Score
Moderate 50
Insider+$0.3M
Congress
ETF Holdings
Key Statistics
Market Cap$7.7B
52W Range16.82-91.1
Volume1,166,375
Avg Volume1,966,213
Beta0.55
Dividend
Analyst Ratings
6 Buy 0 Hold 1 Sell
Consensus Buy
Company Info
CEORoger A. Jeffs
Employees216
SectorHealthcare
IndustryMedical - Pharmaceuticals
IPO Date2018-07-26
419 Davis Drive
Morrisville, NC 27560
US
919 328 4400
About Liquidia Corporation

Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.

Recent Insider Trades

NameTypeSharesPriceDate
Bloch Stephen M S-Sale 96,400 $89.44 2026-07-23
Bloch Stephen M S-Sale 3,600 $90.71 2026-07-23
Bloch Stephen M S-Sale 37,406 $87.70 2026-07-22
Bloch Stephen M S-Sale 48,032 $88.65 2026-07-22
Bloch Stephen M S-Sale 14,562 $89.24 2026-07-22

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms